STRO Valuation

Sutro Biopharma Inc

Add to Watchlist

Advanced Chart

0.857

-0.038(-4.244%)1D

Overview
Forecast
Valuation
Earnings

STRO Relative Valuation

STRO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, STRO is overvalued; if below, it's undervalued.

Historical Valuation

Sutro Biopharma Inc (STRO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.01 is considered Undervalued compared with the five-year average of -3.24. The fair price of Sutro Biopharma Inc (STRO) is between 5.01 to 10.08 according to relative valuation methord. Compared to the current price of 0.86 USD , Sutro Biopharma Inc is Undervalued By 82.9%.

Relative Value

Fair Zone

5.01-10.08

Current Price：0.86

82.9%

Undervalued

-0.50

Trailing

Forward

1.52

EV/EBITDA

Sutro Biopharma Inc. (STRO) has a current EV/EBITDA of 1.52. The 5-year average EV/EBITDA is -0.63. The thresholds are as follows: Strongly Undervalued below -4.88, Undervalued between -4.88 and -2.75, Fairly Valued between 1.49 and -2.75, Overvalued between 1.49 and 3.61, and Strongly Overvalued above 3.61. The current Forward EV/EBITDA of 1.52 falls within the Overvalued range.

0.78

EV/EBIT

Sutro Biopharma Inc. (STRO) has a current EV/EBIT of 0.78. The 5-year average EV/EBIT is -1.44. The thresholds are as follows: Strongly Undervalued below -6.79, Undervalued between -6.79 and -4.11, Fairly Valued between 1.24 and -4.11, Overvalued between 1.24 and 3.91, and Strongly Overvalued above 3.91. The current Forward EV/EBIT of 0.78 falls within the Historic Trend Line -Fairly Valued range.

2.01

Sutro Biopharma Inc. (STRO) has a current PS of 2.01. The 5-year average PS is 9.06. The thresholds are as follows: Strongly Undervalued below -5.83, Undervalued between -5.83 and 1.61, Fairly Valued between 16.50 and 1.61, Overvalued between 16.50 and 23.95, and Strongly Overvalued above 23.95. The current Forward PS of 2.01 falls within the Historic Trend Line -Fairly Valued range.

-0.56

P/OCF

Sutro Biopharma Inc. (STRO) has a current P/OCF of -0.56. The 5-year average P/OCF is -6.43. The thresholds are as follows: Strongly Undervalued below -26.98, Undervalued between -26.98 and -16.70, Fairly Valued between 3.85 and -16.70, Overvalued between 3.85 and 14.13, and Strongly Overvalued above 14.13. The current Forward P/OCF of -0.56 falls within the Historic Trend Line -Fairly Valued range.

-1.06

P/FCF

Sutro Biopharma Inc. (STRO) has a current P/FCF of -1.06. The 5-year average P/FCF is -3.62. The thresholds are as follows: Strongly Undervalued below -10.25, Undervalued between -10.25 and -6.94, Fairly Valued between -0.31 and -6.94, Overvalued between -0.31 and 3.00, and Strongly Overvalued above 3.00. The current Forward P/FCF of -1.06 falls within the Historic Trend Line -Fairly Valued range.

Sutro Biopharma Inc (STRO) has a current Price-to-Book (P/B) ratio of -2.26. Compared to its 3-year average P/B ratio of 1.30 , the current P/B ratio is approximately -274.40% higher. Relative to its 5-year average P/B ratio of 1.74, the current P/B ratio is about -230.30% higher. Sutro Biopharma Inc (STRO) has a Forward Free Cash Flow (FCF) yield of approximately -346.84%. Compared to its 3-year average FCF yield of -77.66%, the current FCF yield is approximately 346.60% lower. Relative to its 5-year average FCF yield of -53.46% , the current FCF yield is about 548.83% lower.

-2.26

P/B

Median3y

1.30

Median5y

1.74

-346.84

FCF Yield

Median3y

-77.66

Median5y

-53.46

Competitors Valuation Multiple

The average P/S ratio for STRO's competitors is 45.58, providing a benchmark for relative valuation. Sutro Biopharma Inc Corp (STRO) exhibits a P/S ratio of 2.01, which is -95.58% above the industry average. Given its robust revenue growth of 147.98%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Repare Therapeutics Inc

Applied Therapeutics Inc

Context Therapeutics Inc

-22.37

75.35M

Performance Decomposition

Market capitalization of STRO decreased by 75.23% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 25.71M to 63.75M.

The secondary factor is the Margin Expansion, contributed -90.34%to the performance.

Overall, the performance of STRO in the past 1 year is driven by Revenue Growth. Which is more sustainable.

147.98%

25.71M → 63.75M

Revenue Growth

-90.34%

-186.80 → -18.04

Margin Expansion

-132.87%

1.04 → -0.34

P/E Change

-75.23%